Bonterra Energy
OTCMKTS:BNEFFBonterra Energy Corp., a conventional oil and gas company, engages in the development and production of oil and natural gas in Canada. Its principal properties include Pembina Cardium, a conventional oil field, at the Pembina and Willesden green fields located in central Alberta; and holds 100% interest in the Montney properties that consist of approximately 28,880 acres located in the north of Grand Prairie, Alberta. The company was incorporated in 2013 and is headquartered in Calgary, Canada.
Liquefied Natural Gas
OTCMKTS:LNGLYLiquefied Natural Gas Limited, together with its subsidiaries, engages in the identification and progression of liquefied natural gas (LNG) development projects to facilitate the production and sale of LNG. It operates through LNG Infrastructure, and Technology and Licensing segments. The company's projects include the Magnolia LNG project located in Lake Charles, Louisiana, the United States; and the Bear Head LNG project situated in Point Tupper, Richmond County, Nova Scotia, Canada. It also designs, develops, owns, and patents OSMR LNG liquefaction process. The company is headquartered in Houston, Texas.
Paladin Energy
OTCMKTS:PALAFPaladin Energy Ltd develops, explores for, owns, and operates uranium mines in Australia, Canada, and Africa. The company operates through Exploration, Namibia, and Australia segments. Its flagship project is the Langer Heinrich mine located in the Namib Desert in Namibia. The company was formerly known as Paladin Resources Ltd and changed its name to Paladin Energy Limited in November 2007. Paladin Energy Ltd was incorporated in 1993 and is headquartered in Perth, Australia.
ReNeuron Group
OTCMKTS:RNUGFReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
The Taiwan Fund
NYSE:TWNThe Taiwan Fund, Inc. is a closed-ended equity mutual fund launched and managed by Nomura Asset Management U.S.A. Inc. It invests in the public equity markets of Taiwan. The fund seeks to invest in stocks of companies operating across diversified sectors. It employs fundamental analysis focusing on such factors as overall growth prospects, competitive position in the respective industry, technology, research, and development, productivity, labor costs, raw material costs and sources, profit margins, return on investment, capital resources, government regulation, and management to create its portfolio. The fund benchmarks the performance of its portfolio against the TAIEX Total Return Index. The Taiwan Fund, Inc. was formed on December 23, 1986 and is domiciled in the United States.